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RESUMO 
 
O cancro da mama é o segundo cancro mais incidente a nível mundial e representa 
a quinta causa de morte por cancro. Em Portugal é o cancro mais incidente e a principal 
causa de morte por cancro no sexo feminino. Apesar dos programas de rastreio baseados 
na mamografia, implementados sobretudo nos países mais desenvolvidos, permitirem o 
diagnóstico de muitos cancros num estadio inicial, levando a uma diminuição da taxa de 
mortalidade por cancro da mama nestes países, esta é ainda uma das mais elevadas. 
Devido à grande heterogeneidade do cancro da mama, múltiplos estudos têm sido 
realizados de forma a melhor caracterizar esta doença e, consequentemente, melhor 
estratificar os doentes. Foram descritos quatro subtipos moleculares principais no cancro 
da mama que apresentam diferente valor prognóstico. Contudo, a sua caracterização na 
prática clínica apresenta, ainda, limitações. A descoberta do papel da epigenética, 
nomeadamente da metilação do DNA, na regulação da normal expressão génica e o seu 
papel na carcinogénese de diversas neoplasias, é responsável pelas inúmeras publicações 
nesta área de investigação nos últimos anos. A metilação aberrante de diversos genes 
associados ao cancro da mama está largamente descrita, tendo sido proposta como 
biomarcador de diagnóstico e prognóstico. 
Este trabalho teve como principal objetivo verificar se a metilação de um painel de 
seis genes (APC, BRCA1, CCND2, FOXA1, RASSF1A e SCGB3A1) possui potencial para 
ser utilizado na detecção/diagnóstico dos diversos subtipos moleculares de cancro da 
mama. 
Os níveis de metilação do promotor dos seis genes foram avaliados por PCR 
quantitativo específico para metilação em DNA modificado por bissulfito de sódio em 137 
amostras de tecido de cancro da mama e 18 amostras de mama normal. Para a 
determinação do desempenho diagnóstico da metilação destes genes foi realizada a 
análise de curva ROC. Os níveis de metilação foram ainda associados com os subtipos 
moleculares (previamente determinados por imuno-histoquímica) e com as variáveis 
clinico-patológicas relevantes. A análise de sobrevivência livre de doença e específica de 
doença foi realizada segundo o método de Kaplan-Meyer, utilizando o teste de log-rank e 
a regressão de Cox para comparações e tendo-se avaliado o valor prognóstico da 
metilação dos genes estudados. 
Os nossos resultados permitiram confirmar o potencial diagnóstico da metilação do 
DNA para cinco dos seis genes estudados. A utilização de um painel baseado na metilação 
de três genes (APC, FOXA1 e RASSF1A) permitiu a descriminação de amostras 
neoplásicas de amostras normais com uma especificidade, sensibilidade e acuidade 
superiores a 94%. Não foi encontrada nenhuma associação entre a metilação dos seis 
vii 
 
genes e qualquer subtipo molecular. Contudo, os níveis de metilação do promotor do APC 
e do SCGB3A1 correlacionaram-se com os subtipos histológicos (nomeadamente os 
carcinomas de subtipos especiais) e a metilação do FOXA1 e do RASSF1A com o status 
dos recetores hormonais. Na nossa série níveis elevados de metilação do FOXA1 
associaram-se com uma pior sobrevivência específica de doença. 
Este trabalho confirmou o potencial do uso da metilação do DNA como biomarcador 
de diagnóstico com um painel com alta sensibilidade e especificidade capaz de detetar 
qualquer subtipo molecular de cancro da mama. Adicionalmente, os resultados revelaram 
o potencial da metilação do FOXA1 como fator prognóstico, até à data não reportado na 
literatura. 
Este trabalho permitiu, assim, revelar novos potenciais marcadores de diagnóstico 
e prognóstico para o cancro de mama cuja validação em estudos prospetivos poderá 
revelar grande utilidade clínica.  
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ABSTRACT 
 
Breast cancer is the second most incident cancer worldwide and the fifth cause of 
cancer-related death. In Portugal, it is the most incident cancer and the leading cause of 
cancer death among women. Although mammography-based screening implementation in 
developed countries allowed for mortality rate decrease, it is still very high. Breast cancer 
is a heterogeneous disease and multiples studies have attempted to better understand this 
disease and, consequently, better stratify breast cancer patients. Four major molecular 
subtypes are recognized in breast cancer, which have different prognosis. However, the 
use of molecular characterization in clinical practice is still limited. Epigenetics mechanisms, 
such as DNA methylation, are important gene expression regulators in normal cells and its 
deregulation in cancer has been increasingly recognized. Aberrant DNA methylation in 
breast cancer has been widely described and several studies have unveiled its diagnostic 
and prognostic potential. 
The main goal of this study was to determine the diagnostic and prognostic potential 
of promoter methylation levels of six genes (APC, BRCA1, CCND2, FOXA1, RASSF1A and 
SCGB3A1), as well as its ability to discriminate among the breast cancer molecular 
subtypes. 
The methylation levels of all candidate genes were assessed by quantitative 
methylation-specific PCR using sodium-bisulphite modified DNA from fresh frozen samples 
of breast cancer (n=137) and normal breast (n=18). To assess the diagnostic potential, 
ROC curve analysis was performed. Promoters’ methylation levels were correlated with 
molecular subtypes (previously determined by immunohistochemistry) and with standard 
clinicopathological parameters. To verify the prognostic potential of methylation levels, log-
rank test and Cox regression was performed for disease-free and disease-specific survival. 
Five out of the six candidate genes demonstrated diagnostic potential. A three-gene 
methylation panel (APC, FOXA1 and SCGB3A1) could discriminate normal from cancerous 
breast tissue with specificity, sensitivity and accuracy above 94%. Methylation levels of 
these six genes did not correlate with any molecular subtype of breast cancer. 
Nevertheless, APC and SCGB3A1 methylation levels associated with histological subtypes 
(specifically with special subtype carcinomas) whereas FOXA1 and RASSF1A methylation 
levels associated with hormone receptor status. In our series, high FOXA1 methylation 
levels associated with shorter disease-specific survival. 
Thus, we confirmed the diagnostic potential of DNA methylation levels in breast 
cancer. Importantly, the three-gene panel displayed high specificity, sensitivity and 
accuracy for breast cancer detection regardless of molecular subtype. Moreover, the results 
uncovered the prognostic potential of FOXA1 promoter methylation. 
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This work revealed new potential diagnostic and prognostic biomarkers for breast 
cancer and its validation in large prospective studies is mandatory to evaluate its clinical 
usefulness. 
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BREAST CANCER 
EPIDEMIOLOGY 
Breast cancer (BrC) is the 2nd cancer more incident worldwide, corresponding about 
to 11.9% of all cancer incidence. Within an estimated 1.67 million new cases in 2012 is the 
most common cancer in women (about 25% of all cancer). The BrC incidence is higher in 
more developed regions, such Northern America, Australia, and Northern and Western 
Europe (Figure 1)[1]. These differences are mainly due to screening programs that allow 
the detection of early invasive cancers in the former countries [2].  
 
Figure 1 – Estimated Age-Standardized Breast Cancer Incidence Worlwide in 2012[3]. 
Despite the high incidence of BrC is the 5th cause of death by cancer due to the 
access of health care and the early cancer detection. Worldwide in 2012 522 thousand 
deaths by BrC were estimated [1, 2]. 
In Europe, BrC was the leading cancer in both sexes (Figure 2). In 2012 were 
estimated about 484 (per 100 000) BrC new cases and 94.2 (per 100 000) deaths [4]. 
 
Figure 2 – Estimated number of cancer cases for both sexes in Europe 
in 2012 [3]. 
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In Portugal, BrC was the leading cancer in 2012 with 67.6 (per 100 000) new cases 
and the 1st cause for cancer death in women with 13.1 (per 100 000) deaths (Figure 3)[4]. 
 
Figure 3 – Estimated Age-Standardized Incidence and Mortality Rates (per 
100 000) in Portugal in 2012 [3]. 
This reality has turned BrC one of the main interest research field. Despite all the 
improvement in cancer early detection and treatment, BrC remains the foremost cause of 
cancer-related death in women due to development of recurrent and/or metastatic disease 
[1]. 
 
 
RISK FACTORS  
The BrC is a complex disease with multiple factors associated. These factors include 
demographic, genetics, familiar factors and hormone exposure among others. Some of 
these factors are clustered in Table 1 by relative risk categories. 
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Table 1 – Magnitude of risk of known BrC risk factors. Adapted from [5, 6]  
Relative Risk <2 Relative Risk 2-4 Relative Risk >4 
 Early menarche 
 Late menopausal 
 Nulliparity 
 Hormone replacement 
therapy 
 Oral contracpetive use 
 Alcohol use 
Postmenopausal obesity 
 One first-degree relative 
with BrC 
 Age > 30 years for first 
delivery 
 Proliferative breast 
disease 
 
 BRCA 1 or BRCA2 
Mutations  
 Atypical hyperplasia 
 Radiation exposure at 
early age 
BrC - Breast Cancer 
 
Demographic Factors 
BrC incidence increases sharply with age, being commonly diagnosed in patients 
between 45 and 74 years (Figure 4)[7]. According to the Surveillance Epidemiology, and 
End Results (SEER) database, in the United States, the probability of a woman for 
developing BrC is 1 in 8 over a lifetime: 1 in 202 from birth to age 39 years of age, 1 in 26 
from 40 to 59 years, and 1 in 28 from 60 to 69 years[8].  
 
Figure 4 – Percent of new breast cancer cases by age group 
(Surveillance, Epidemiology, and End Results [SEER], 2009-
2013) From [7]. 
Genetics and Familiar Factors 
The family history of BrC is highly associated BrC risk. Women who have a first-
degree relative with BrC history, have a higher risk of BrC. Moreover, this risk increases if 
the family member affected was diagnosed at young age (less than 40 years) [5, 6, 9]. 
Likewise, there are several syndromes associated with an increase in BrC risk. The 
most frequent hereditary mutations occur in BRCA1, DNA repair associated (BRCA1) and 
BRCA2 genes which are highly associated with BrC in younger age and premenopausal 
women. Less than 10% of all BrC cases are due to mutations in these genes, carriers of 
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BRCA1 and BRCA2 mutations have an estimated lifetime risk of BrC between 26% and 
85%. Additional genes such as Tumor Protein p53 (TP53), Phosphatase and Tensin 
homolog (PTEN) and Lynch Syndrome associated genes are implicated in familiar BrC [5, 
6, 9]. 
Reproductive Factors and Hormone Exposure 
The risk of BrC is highly associated with women’s reproductive history. Women with 
menarche at early age who remains nulliparous or with the first delivery at late age (30 
years or later) have an increased risk of BrC development [5, 6, 9]. Late age at menopause 
is also risk factor to development of BrC [6, 9]. Indeed, these risk factors are associated 
with the exposure to elevated levels of estrogens, therefore, the surgical cessation of 
estrogen production by oophorectomy is protective against BrC development [6]. Moreover, 
the use of oral contraceptives or postmenopausal hormone-replacement therapy (HRT) 
associates with a slight but significant increase of BrC risk. The increased risk varies with 
usage duration and, in the case of HRT, if includes estrogen alone or estrogen plus 
progestin [5, 6, 9]. 
Dietary and Lifestyle Factors 
The most emerging lifestyle factor for postmenopausal BrC is obesity. Indeed, an 
increased body mass index raises the risk to BrC due to elevation of endogenous estrogen 
concentrations in plasma. However, in premenopausal women, obesity seems have the 
oppose effect. Thus, the weight and its variation in lifetime seems to play a role in BrC risk 
[6, 9].  
Moreover, a healthy diet with high intake of fruit and vegetables seems to decrease 
BrC risk, while high caloric diet and high red meat intake and saturated animal fat have the 
opposed effect [5, 9]. The consumption of alcohol is, as well, largely associated with an 
increased risk for BrC. These findings may be associated with endogenous hormone levels. 
Similarly, the active cigarrete smoking has been associated with an increase of BrC risk. 
However, the same is not described to passive smoking which only seem to impact in 
premenopausal BrC [6, 9]. 
Environmental Factors 
The exposure to ionizing radiation increases BrC risk, moreover this increase arises 
with exposure in young age. Likewise, women who receive radiation to treatment of 
Hodgking lymphoma at young age have a higher risk to BrC [5, 6]. 
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Benign Breast Disease 
Benign Breast Disease is classified in two main categories: proliferative and non-
proliferative breast lesions. Although non-proliferative lesions do not carry any BrC risk, the 
proliferative lesions are associated with a higher risk to BrC. Among these, atypical 
hyperplasia is the lesion with the higher risk to BrC, which significantly increases if 
associated with family history of BrC [5, 6]. 
 
DIAGNOSTIC, PROGNOSTIC FACTORS AND TREATMENT  
Screening and Diagnosis 
The diagnosis of BrC is a multidisciplinary task that requires several specialists in 
oncologic field such as surgeons, clinicians, pathologists and radiologists, among others.   
The most common clinical presentation of BrC is a palpable mass. However, BrC 
may be presented clinically as persistent areas of pain or tenderness or nipple discharge 
[9, 10]. 
Due to the high incidence of BrC, eighteen European countries have implemented 
a national or regional population-based mammography screening program, in order to 
detect BrC at pre-clinical stage [11]. Typically, the screening programs plan to carry out a 
mammography every two years in women between 50 to 69 years old [11]. For women with 
high risk of BrC (e.g. women with BRCA1 mutation) is recommended annual magnetic 
resonance imaging alongside or alternating with mammography every 6 months. High risk 
women should start the screening 10 years younger than the youngest case in the family  
[11]. 
The diagnosis of BrC includes the clinical examination in concomitance with imaging 
techniques, and pathological confirmation [11]. The pathological confirmation can be 
performed by fine-needle biopsy (FNB) or needle-core biopsy (NCB) with a good sensitivity 
for both techniques in palpable lesions. However, NBC presents higher sensitivity for 
detection of BrC in impalpable lesions, currently being the preferential method for 
pathological confirmation [9, 11]. The NCB is recommended for evaluation of FNA 
suspicious findings and evaluation of microcalcifications. When preoperative systemic 
therapies are planned, NCB is mandatory to ensure histopathological diagnosis and the 
assessment the established immunostaining markers  [9, 11]. 
Histological Subtypes  
BrC is a highly heterogenous disease and the current World Health Organization 
Classification of Tumours of Breast identifies more than 20 histological types. 
7 
 
The majority of the BrC have their origin at epithelial cells and can be subdivided 
into in situ and invasive carcinomas. The in situ carcinomas are defined as pre-invasive 
lesions in which neoplastic epithelial cells proliferate confined to the ductal/lobular tree of 
the breast without evidence of invasion through the basement membrane [12, 13]. In situ 
carcinomas are further subdivided in lobular carcinoma in situ (LCIS) e Ductal carcinoma in 
situ (DCIS). DCIS is more frequent than LCIS and these two lesions are distinguished by 
difference in the architectural and cytological features and not of the micro-anatomical site 
of origin (ducts or lobules) [9, 13]. The DCIS is an infrequent diagnosis in countries without 
mammographic screening programmes once it is present only in 2-3% of palpable BrC. With 
the implementation of mammographic screening programmes the DCIS represents 20-25% 
of newly diagnosed BrC. [9, 12].  
Nonetheless, the invasive carcinomas are the most common BrC lesions (70-80% 
of malignant neoplasia of breast)[13]. The invasive carcinomas can generally be grouped 
in two categories: invasive carcinoma of no special type (NST) and special subtypes 
carcinomas (SSC). The invasive NST carcinoma and the invasive lobular carcinoma (ILC) 
represent the major types of BrC (Figure 5) [9, 12].  
The invasive NST carcinoma is also known as ductal carcinoma NST or invasive 
ductal carcinoma (IDC) and represents up to 75% of all invasive carcinomas (Figure 5 A) 
[9]. This designation categorizes a heterogeneous group comprising the tumors that cannot 
be identified as any SSC and, consequently, morphological features vary among different 
tumors [9]. If a tumor 10-49% of a SSC pattern and the remaining are NST carcinoma it will 
be categorized as mixed type carcinoma (MTC) [9].  
ILC is the most common of the SSC representing 5-15% of all BrC (Figure 5 B). 
Clinically most the women present an ill-defined palpable mass and the classic pattern is 
characterized by a proliferation of small cells, which lack cohesion and appear arranged in 
single-file linear cords that invade the stroma or individually dispersed  trough a fibrous 
connective tissue [9]. 
 
Figure 5 – Hematoxylin and eosin stained sections of the two most common histological subtypes of Breast 
Cancer, 200x. A – Ductal Invasive Carcinoma; B – Lobular Invasive Carcinoma. 
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SSC category includes also more than 10 others histological types which the 
frequency is much lower than the subtypes described above, such as mucinous carcinoma, 
carcinoma with medullary features, invasive papillary carcinoma and other. 
Grading 
All the breast tumors are graded based on assessment of tubule/gland formation, 
nuclear pleomorphism and mitotic counting. Currently, the Nottingham combined histologic 
grade (the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system) is 
widely accepted [14] (Table 2). Grade is a powerful prognostic factor and it is a key 
component for clinical decision-making [9]. 
Table 2 – Nottingham combined histologic grade. Adapted from[14] 
Criteria 
Score 
1 2 3 
Glandular/Tubular 
differentiation 
>75 % of tumor area 
forming glandular/ 
tubular structures 
10-75 % of tumor 
area forming 
glandular/ tubular 
structures 
<10 % of tumor area 
forming glandular/ 
tubular structures 
Nuclear 
pleomorphism 
Small nuclei with little 
increase in size in 
comparison with 
normal breast 
epithelial cells, 
regular outlines, 
uniform nuclear 
chromatin, little 
variation in size 
Cells larger than 
normal with open 
vesicular nuclei, 
visible nucleoli, and 
moderate variability 
in both size and 
shape 
Vesicular nuclei, 
often with prominent 
nucleoli, exhibiting 
marked variation in 
size and shape, 
occasionally with 
very large and 
bizarre forms 
Mitotic Counting ≤4/10 HPF 5–9/10 HPF ≥10/10 HPF 
 Overall Score 
1 2 3 
Total Score 3-5 6 or 7 8 or 9 
HPF – High-power field 
 
Staging and Prognosis 
All the patients diagnosed with BrC are staged in order to evaluated disease 
extension and patient’s prognosis. The most widely accepted system to stage BrC patients 
is TNM system published by the American Joint Committee on Cancer (AJCC)/ Union for 
International Cancer Control (UICC) [9]. This system combines information about the extent 
of cancer in primary site (tumor or T), the regional lymph node (nodes or N) and spread to 
the distant metastatic sites (metastases or M) [9, 15]. The combination of these 3 
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parameters allows for the establishment of five stages (0, I, II, III and IV) that summarize 
the information for making decisions concerning disease control and determine the value of 
systemic therapy (Appendix I). Moreover, stage is essential for comparison in clinical trials, 
epidemiological studies and others investigations [9]. 
Both clinical and pathological staging are used in patients with BrC. The clinical 
staging (c) (Appendix II) is determined using information identified prior to surgery or 
neoadjuvant therapy. It includes physical examination, with careful inspection and palpation 
of the skin, mammary gland, and lymph nodes, imaging (such as mammography and 
ultrasound), and pathologic examination of the breast or other tissues as appropriate to 
establish the diagnosis of breast carcinoma (e.g. FNB or NCB) [11, 15]. The pathologic 
staging (p) (Appendix II) includes information defined at surgery. It includes all data used 
for clinical staging, plus data from surgical exploration and resection as well as pathologic 
examination (gross and microscopic) of the primary carcinoma, regional lymph nodes, and 
metastatic sites (if available) [15]. 
Despite the information provided by TNM staging, for each BrC patient is also 
important to assess other biomarkers of prognostic outcome and predictive therapy 
response [11]. Currently, in the routine clinical management of BrC patients, estrogen 
receptor (ER) and progesterone receptor (PR) status is evaluated by immunohistochemistry 
(IHC) along with Erb-b2 receptor tyrosine kinase 2 (ERBB2) assessed by IHC and/or in situ 
hybridization. 
Estrogen Receptor 
ER is a nuclear transcription factor that stimulates the growth of normal breast 
epithelial cells when is active by hormone estrogen. ER is a crucial player in breast 
carcinogenesis, whose inhibition forms the mainstay of BrC endocrine therapy [9, 16]. By 
IHC, about 75-80% of invasive BrC are positive for ER expression and the proportion of 
positive cells ranges from 1% to 100% [9, 10]. 
ER positive tumors are associated with well-differentiated, less aggressive tumors 
and, consequently, with a better outcome when compared with ER negative tumors. 
However, ER expression alone has a limited prognostic value [16]. 
Moreover, the ER expression is a strong predictive marker of response to endocrine 
therapies such selective ER modulators (e.g. tamoxifen) or aromatase inhibitors (e.g. 
letrozole) [9, 16]. 
Progesterone Receptor 
PR expression suggests an active ER signaling pathway. The activation of PR by 
progesterone hormone stimulates cell growth. About 60-75% of invasive BrC are positive 
for PR by IHC and tumors PR positive are rarely ER negative [9, 16]. RP positive tumors 
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also associate with response to endocrine therapies. Moreover, tumors positive for ER but 
negative for PR are less responsive to these therapies than tumors positive for both 
hormone receptors [9, 16]. 
Erb-b2 receptor tyrosine kinase 2 
Erb-b2 receptor tyrosine kinase 2 (ERBB2) gene [also known as Human epidermal 
growth factor 2 receptor (HER2)] is localized in chromosome 17 and codes for a growth 
factor receptor present in breast epithelial cell surface. This oncogene is amplified in 13% 
to 20% of BrC tumors with overexpression of protein. Moreover, about 55% of these cases 
do not express hormone receptors (ER and PR) [16]. The prognostic value of ERBB2 
overexpression is complex once ERBB2 expression is associated with poor prognosis and 
at the same time to a favorable response to ERBB2-target therapies such as trastuzumab 
(a therapy targeting the ERBB2 protein) [9, 16].  
Emerging prognostic assays  
In the last decade, due to the limitations of current prognostic biomarkers, new 
prognostic tests have been developed. Multigene signatures were proposed as being useful 
complementary tools to the current biomarkers that may help in therapeutic decisions. 
These tests are, indeed, multivariate models to predict recurrences [17].   
The first-generation signatures such as Oncotype DX, MammaPrint or Genomic 
Grade Index) are more accurate in predicting recurrence within the first 5 years’ than in later 
years. Differently newer tests, such as PAM50, EndoPredict or Breast Cancer Index, hold 
a better prognostic value for late recurrence keeping the prognostic value for early 
recurrence [17]. 
However, the use of these signatures is limited and the evidence of clinical 
usefulness of some signatures is still weak. The American Society of Clinical Oncology 
(ASCO) already endorsed some of those signatures only for ER/PR-positive, ERBB2-
negative and lymph node negative BrC. The ASCO 2016 guidelines only recognized the 
usefulness of OncotypeDX, EndoPredict, Breast Cancer Index and PAM50 to guide 
decision on adjuvant systemic therapy [18]. 
 
Treatment 
The BrC treatment is a complex work-up which combines the TNM staging and the 
prognostic biomarkers status. The treatment decision in BrC should always be provided by 
a multidisciplinary clinical team and may include one or more therapeutic strategies, 
including surgery, radiotherapy, endocrine therapy, chemotherapy and target therapy [11]. 
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Surgery 
Surgery is usually the primary treatment for early-stage BrC. About 60-80% of BrC 
patients are amenable for conservative breast surgery (wide local excision) followed by 
radiotherapy [11, 19]. However, for some cases mastectomy remains as the best option 
due to: tumor size (relative to breast size), tumor multi-centricity, inability to achieve 
negative surgical margins after multiple resections, contraindications to radiotherapy, or 
simply for patient choice [11]. 
Radiation Therapy 
Radiation Therapy is highly recommended after a conservative breast surgery. A 
specific planning for each patient is of major importance in order reduce the irradiation of 
adjacent organs and ensure the target dose delivery. Thus, it is recommend a computer 
tomography-based treatment planning [19]. 
The radiation of entire breast reduces the risk of recurrence by 15% in first 10 years 
and reduces the risk of mortality by BrC in 4% [11, 19]. In patients that undergo mastectomy 
and display positive lymph nodes, radiation therapy reduces the 10-year risk of any 
recurrence (including locoregional and distant) by 10% and the 20-year risk of breast 
cancer-related mortality by 8% [11]. 
Chemotherapy 
Chemotherapy decision for BrC treatment is complex and takes into account the 
predicted sensitivity to particular treatment methods and benefit from its use along with 
individual risk of relapse [20]. Chemotherapy can be used as adjuvant therapy or as 
neoadjuvant therapy. Neoadjuvant chemotherapy is recommended in locally advanced BrC 
or in and large ‘operable’ cancers, in particular when mastectomy is required due to tumor 
size, since it may reduce the extent of surgery needed [11].  
The benefit of adjuvant chemotherapy is higher in ER-negative BrC (either positive 
or negative for ERBB2). However, ER-positive BrC with ERBB2 amplification or high-risk of 
recurrence may also benefit of adjuvant chemotherapy [20, 21].  
 
Endocrine Therapy 
Endocrine Therapy is recommend to all BrC positive for hormone receptors. The 
prescription’s choice is primarily determined by patient’s menopausal status. In 
premenopausal, tamoxifen 20 mg/day for 5–10 years is standard. When patients become 
postmenopausal during the first 5 years of tamoxifen, a switch to an aromatase inhibitor 
(such as letrozole), seems to be particularly beneficial [11, 20]. High risk premenopausal 
patients should be considered for ovarian function suppression as well [21]. In 
postmenopausal patients, tamoxifen and aromatase inhibitors are valid options. Aromatase 
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inhibitors associate with increased disease-free survival, but no significant impact was 
observed in overall survival for treatment up to 5 years. Moreover, there is no proven benefit 
for the routine use of aromatase inhibitors for more than 5 years [11, 20].  
Target Therapy 
ERBB2 target therapy is the most used target therapy in BrC treatment in patients 
with ERBB2 overexpression/amplification. The monoclonal antibody against ERBB2, 
Trastuzumab, combined with chemotherapy reduces the recurrence risk by approximately 
50% when compared with chemotherapy alone, translating into a 10% absolute 
improvement in long-term disease-free survival and 9% increase in 10- year overall survival 
[11, 20]. Trastuzumab is approved for treating patients with node-positive disease and for 
node-negative patients with tumors greater than 1 cm. However, due to high risk for 
recurrence, N0 staged patients with tumors less than 1 cm, should be also be considered 
for this treatment, particularly if they are ER-negative disease [11, 19]. 
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MOLECULAR BIOLOGY OF BREAST CANCER 
BrC is a multifactorial disease resulting from several genetics and epigenetics 
aberrations. In past decades, multiple efforts have been made in order to better understand 
BrC disease and improve the diagnostic, prognostic and predictive biomarkers and unsure 
a better treatment. 
GENETICS 
Several genetic aberrations are described in BrC, including point mutations, 
deletions, amplifications, rearrangements, translocations, and duplications. These DNA 
alterations result in oncogenes’ activation and of tumor suppressors’ silencing (Figure 6) 
[22]. 
PI3K and Ras-MEK signaling pathways are active by ERBB2 amplification in about 
15% of BrC. The activation of these pathways leads to tumor cell growth and proliferation 
[10, 23]. Likewise, cell cycle control pathways are deregulated in BrC. In about 10-12% of 
the patients, cyclin D1 is amplified which acts upon the Rb protein releasing E2F 
transcription factor that will induce cell cycle entrance [10, 23]. Moreover, DNA damage and 
genomic instability are associated with BrC. BRCA1 and BRCA2 mutations are associated 
with DNA repair deficiency and TP53 mutations are associated with cell cycle checkpoints 
failure [10, 12, 23]. Single Nucleotide Polymorphisms (SNPs) and copy number variations 
(CNVs) can also have an impact in BrC incidence. Additionally to inherited mutations, SNPs 
and CNVs provide genetic background for BrC development [23]. 
 
 
Figure 6 – Scheme of the mechanism related with BrC carcinogenesis with the 
most frequent genes involved. From [22] 
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Molecular Subtypes of Breast Cancer 
BrC is a complex and heterogeneous disease in which tumors with the same 
histological types and identical stage often present divergent outcomes and therapeutic 
responses. In order to better understand these differences and due to the advances in high 
throughput technologies, multiples studies were made to adequately profile and classify BrC 
tumors [24, 25].  
Microarray-based gene expression profiling endorsed specific molecular subtypes 
of BrC with coherent expression patterns, reflecting variation in the patient’s prognosis [24, 
26]. The molecular classification of BrC led to identification of widely accepted major 
subtypes that carry prognostic value (Figure 7)[26].  
 
Figure 7 – Molecular intrinsic subtypes of Breast Cancer (A) Hierarchical clustering of 115 tumor 
tissues and 7 nonmalignant tissues using the “intrinsic” gene set. Experimental dendrogram 
showing the clustering of the tumors into five subgroups. Branches corresponding to tumors 
with low correlation to any subtype are shown in gray. (top panel) Gene cluster associated with 
each subtype (bottom panel).(B) Kaplan–Meier analysis of disease outcome in two patient 
cohorts. Time to development of distant metastasis in the 97 sporadic cases from van’t Veer et 
al. (left panel). Overall survival for 72 patients with locally advanced breast cancer in the Norway 
cohort (right panel). Adapted from [26] 
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The first main division refers to the expression of luminal epithelial cells, including 
the ER and those that were negative for these genes. The ER positive/luminal subtype 
represents the majority of BrC (70-80%) and are generally associated with good prognosis 
[24, 26, 27]. Furthermore, luminal carcinomas can be subdivided in Luminal A and Luminal 
B subtypes according to ERBB2 expression and proliferation rates. Luminal B is associated 
with ERBB2 expression and/or high proliferation rates and, consequently, with worse 
prognosis than Luminal A tumors [26, 27]. 
In the non-luminal BrC, the ERBB2 overexpression subtype characterizes by high 
expression of several genes in the ERBB2 amplicon at 17q22.24 including ERBB2 and 
GRB7 [25]. These cancers usually display a poor prognosis due to high proliferation and 
poor differentiation, however can be a target of targeted therapies [25, 26]. 
Basal-like subtype is also a non-luminal BrC containing a heterogeneous group of 
tumors that may represent up to 15% of all BrC. Moreover, is characterized by strong 
expression of basal epithelial genes and low expression of luminal epithelial. Additionally, 
this subtype is associated with BRCA1 mutations and to the lack of ER, PR and ERBB2 
expression [24-27]. Moreover, over the years basal-like tumors became known as Triple 
Negative BrC (TNBC), although not all basal-tike BrC are TNBC and vice-versa. Seventy to 
eighty percent of TNBC correspond to all basal-like tumors, however the remaining 20-30% 
cases may be one of others subtypes [28]. Furthermore, other subtypes as normal-like and 
claudin-low carcinomas are also described as non-luminal carcinomas. Normal-like present 
similar gene expression pattern as the normal breast, and it is yet not clear whether 
represents a distinct subtype or is due to a technical artifact introduced by low tumor cell 
composition of the sampled specimen [26, 27]. Claudin-low carcinomas are usually TNBC 
characterized by the low to absent expression of luminal differentiation markers, high 
enrichment for epithelial-to-mesenchymal transition markers, immune response genes and 
cancer stem cell- like features [29]. 
Currently the assessment of the four main molecular intrinsic subtypes is being 
tested using IHC (Table 3) [11]. Over the years, studies assessing correlation between IHC 
findings, BrC patients’ prognosis and gene expression profiling, specially, regarding the 
differentiation between luminal A and luminal B BrC have performed. Presently, TNBC are 
classified as basal-like carcinomas, however the search for new markers to a better 
classification of TNBC is currently undergoing [21, 30, 31].  
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Table 3 – Surrogate definitions of intrinsic subtypes of Breast Cancer according to European Society for Medical 
Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up to primary Breast Cancer. 
Adapted from [11]. 
Intrinsic subtype Clinicopathologic surrogate 
definition 
Notes 
Luminal A* ‘Luminal A-like’ 
 ER-positive 
 ERBB2-negative 
 Ki67 low** 
 PR high** 
*if molecular signature is 
available, a low-risk signature 
is associated with Luminal A 
BrC and high-risk signature 
with Luminal B BrC 
 
**Scores should be 
interpreted in the light of local 
laboratory values 
 
***There is ∼80% overlap 
between ‘triple-negative’ and 
intrinsic ‘basal-like’ subtype, 
but ‘triple-negative’ also 
includes some special 
histological types such as 
(typical) medullary and 
adenoid cystic carcinoma 
with low risks of distant 
recurrence. 
Luminal B* ‘Luminal B-like (ERBB2-negative)’ 
 ER-positive 
 ERBB2-negative 
 And either Ki67 high or PR low 
‘Luminal B-like (ERBB2-positive)’ 
 ER-positive 
 ERBB2-positive 
 Any Ki67 and any PR 
ERBB2 
overexpression 
‘ERBB2-positive (non-luminal)’ 
 ERBB2-positive 
 ER and PR absent 
Basal-like ‘Triple-negative (ductal)’*** 
 ER and PR absent 
 ERBB2-negative 
ER – Estrogen Receptor; ERBB2 – Erb-b2 receptor tyrosine kinase 2; PR – Progesterone Receptor; BrC – 
Breast Cancer   
 
EPIGENETICS 
In 1942, Conrad Waddington defined epigenetics as a biology branch which studies 
the interaction between genes and their products and bring the phenotype. However, the 
concept of epigenetics has been changed since then due to increased knowledge on this 
field of research. Epigenetics is, nowadays, recognized as the field of study of heritable 
chances in gene expression that occurs without alteration in DNA sequence. In 2010, the 
NIH Road-map Epigenomics Project defined epigenetics as “heritable changes in gene 
activity and expression (in the progeny of cells or of individuals) and also stable, long-term 
alterations in the transcriptional potential of a cell that are not necessarily heritable”[32]. 
Epigenetic Mechanisms 
Epigenetic mechanisms can be grouped into four main types: DNA methylation, non-
coding RNAs, histone post-translational modifications and histone variants (Figure 8). 
These mechanisms are essential for the normal function of organism. The disruption of one 
17 
 
or more of epigenetic mechanism can result in abnormal gene expression, altering the cell 
homeostasis which conducts to disease development including cancer [32, 33]. 
 
Figure 8 – Scheme of four main mechanisms of epigenetic 
regulation. Adapted from [33] 
Non-coding RNAs 
Non-coding RNAs (ncRNAs) are a class of RNA that do not encode a protein but 
are considered active participants in gene expression regulation. The ncRNAs can be 
further divided according their size into large ncRNAs (more 200 nucleotides) and small 
ncRNAs (less 200 nucleotides) [34]. The most widely known ncRNAs are the microRNA 
(miRNAs). MiRNAs have a 17-25 nucleotides involved in several biological processes such 
as cellular development, differentiation, apoptosis, proliferation, tumor growth among others 
[32]. Aberrant expression of miRNAs was associated with multiple cancers, including BrC 
[35]. 
Histone Post-translational Modifications and Variants 
Eukaryotic chromosomes are composed of essential units of organization, the 
nucleosomes which compose the chromatin. Each nucleosome is composed of an octamer 
of four core histones (H2A, H2B, H3, H4) that is wrapped by a 147-bp stretch of DNA [35]. 
Serving as the basic modules for DNA packaging within a cell, nucleosomes regulate gene 
expression by altering the accessibility of regulatory DNA sequences to transcription 
factors. The incorporation of histone variants, e.g. H3.3 and H2A.Z, into nucleosomes 
influences nucleosome occupancy and thus in gene activity [36].  
Additionally, histone can suffer post-translation modifications which occur mainly in 
the terminal tails. The most studied post-translational modifications are methylation, 
acetylation and phosphorylation. Those post-translational modifications regulate essential 
cellular process such as replication, transcription and repair by either changing the 
chromatin’s availability or by recruiting and/or occluding non-histone effector proteins, which 
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decode the message encoded by the modification patterns [34, 36]. Importantly, both, 
histone variants and histone post-translational modifications have been implicated in 
tumorigenesis [34, 35]. 
DNA Methylation 
DNA methylation is one the most frequent and well-studied epigenetic events. 
The DNA methylation consists in a covalent chemical modification resulting in 
addition of a methyl (CH3) group at the carbon 5 position of the cytosine ring of CpG 
dinucleotides (cytosines that precede guanines). This reaction is carried out by DNA 
methyltransferases (DNMTs) using S-adenosyl methionine as a methyl donor [34].  
In mammalian cells there are five described DNMTs, however only three seems to 
possess methyltransferase activity: DNMT1, DNMT3a and DNMT3b [37]. DNMT1 is 
classified as maintenance DNMT once it is responsible of recognizing hemimethylated CpG 
sites and to ensure the proper inheritance of DNA methylation patterns from mother to 
daughter strand [37, 38]. DNMT3a and DNMT3b are de novo DNMTs and responsible for 
the establishment of the tissue-specific DNA methylation patterns following zygote 
implantation. In normal conditions these enzymes are highly expressed in undifferentiated 
embryonic stem cells but are down-regulated after differentiation [34, 38]. 
About 70-80% of CpG sites are methylated, their distribution in human genome is 
not random and their methylation probabilities depend highly on their position within the 
genome [32, 38]. Genomic regions with high CG content and high frequency of CpG 
dinucleotides are defined as CpG islands [38]. However, DNA methylation does not occur 
exclusively at CpG islands. Indeed, it may also occur in CpG island shores, which are 
regions of lower CpG density that lie in close proximity (~2 kb) of CpG islands [37]. 
In normal cells, active promoters and CpG islands are largely resistant to DNA 
methylation. In opposite, repetitive DNA elements, pericentromeric regions of the genome 
and gene bodies, are often heavily methylated. Moreover, CpG island shores’ methylation 
is also associated with transcriptional inactivation. Most of the tissue-specific DNA 
methylation seems to occur at CpG island shores (Figure 9, left panel) [37, 38]. 
In cancer cells global hypomethylation is accompanied by hypermethylation of 
localized promoter associated CpG islands that usually remain unmethylated in normal cells 
(Figure 9 right panel). Global DNA hypomethylation plays a significant role in tumorigenesis 
and occurs at various genomic sequences usually methylated, such as repetitive DNA 
elements, retrotransposons and gene bodies. DNA hypomethylation is associated to 
increased genomic instability by promoting chromosomal rearrangements. 
Hypomethylation at specific promoters can activate the aberrant expression of oncogenes 
promoting tumor growth and proliferation [34, 36, 37]. Simultaneously, DNA 
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hypermethylation typically affects promoter CpG islands at specific genes inactivating their 
transcription [34, 37]. Indeed, hypermethylation usually affects tumor suppressor genes 
involved in the main cellular pathways such as DNA repair, vitamin response, Ras signaling, 
cell cycle control and apoptosis, among others [34, 37]. 
Hypermethylated promoters have been proposed as a new generation of biomarkers 
since they hold great diagnostic and prognostic promise for clinicians [34]. 
 
Figure 9 – DNA methylation patterns. DNA methylation can occur in different regions of the 
genome. The left panel show the normal scenario in mammalian cells. The right panel show 
the alteration common in cancer cells. Adapted from [37]  
 
DNA Methylation and Breast Cancer 
DNA methylation patterns may differ largely between tumor and normal cells and 
numerous studies reported its important role in carcinogenesis. Similarly to other 
malignancies, BrC globally display a hypomethylation pattern associated with lead to 
oncogenes’ expression. Nonetheless, promoter hypermethylation of several tumor 
suppressor genes are more commonly described in BrC [39]. In fact, DNA global 
hypomethylation and tumor suppressor gene promoter hypermethylation have been 
reported occurring simultaneously as independent processes in breast carcinogenesis and 
at different stages of BrC, being promoter hypermethylation described as an early event in 
BrC directly linked to tumor development [39]. 
The knowledge of DNA methylation implication in tumor initiation and progression in 
BrC unveiled the potential of this epigenetic alterations as diagnostic, prognostic and 
predictive biomarkers [40, 41]. 
20 
 
From the several genes reported, the below mentioned were already proposed as 
putative BrC biomarkers. 
Adenomatosis polyposis coli (APC) 
APC is a tumor suppressor gene that is involved in cell signaling through Wnt 
pathway and plays an important role in cell-cycle regulation and apoptosis [42, 43]. High 
levels of methylation in APC promoter has been described in samples from several 
neoplasms such breast, colon, prostate and lung. In BrC, APC promoter hypermethylation 
seems to be associated with menopausal status and is more frequent in tumors ER and/or 
ERBB2 positive [42-45]. 
BRCA1, DNA repair associated (BRCA1) 
BRCA1 is a tumor suppressor gene important for DNA repair, control of chromatin 
remodeling and transcription, and cell cycle regulation. The BRCA1 promoter methylation 
is a rather uncommon event in BrC [46], however, is was associated with basal-like/TNBC 
subtype [47, 48]. Moreover, methylation might also be detected in serum of BrC patients 
but not in healthy patients [49]. 
Cyclin D2 (CCND2) 
CCND2 is a tumor suppressor gene which is involved in cell cycle regulation. This 
gene was found hypermethylated in BrC samples and may constitute a good diagnosis 
biomarker [45, 50]. The CCND2 promoter methylation has been more frequently found in 
ER positive tumors [43], which represent the majority of breast cancer lesions. 
Fork-head box A1 (FOXA1) 
FOXA1 is a member of the FOX family of transcription factors that is comprised at 
least 40 members. It is a key forkhead transcription factor that can directly bind condensed 
chromatin, displace repressive linker histones and recruit other transcription factors to 
promote transcription [51, 52]. ERα recruits FOXA1 as a cofactor for chromatin binding and 
has been suggested to be responsible for the regulation of nearly 50% ER-target genes 
[52]. In BrC, the hypermethylation of FOXA1 promoter has been associated with basal-like 
carcinoma [52, 53]. 
Ras association domain family 1 isoform A (RASSF1A) 
RASSF1A is a tumor suppressor gene frequently silenced by respective promoter 
hypermethylation in several human cancers. This gene is implicated in multiple pathways 
that control cell-cycle, apoptosis and cell motility and invasion [54]. Similarly to APC, 
RASSF1A promoter was reported to be frequently hypermethylated in several neoplasms. 
In BrC, RASSF1A promoter hypermethylation was associated with menopausal status and 
with early stages of BrC development [42, 50, 55]. Similarly, RASSF1A inactivation by 
21 
 
methylation is more frequently found in ER and/or ERBB2 positive tumors and was reported 
to have predict overall survival and disease-free survival [43, 50, 56, 57]. 
Secretoglobin family 3A member 1 (SCGB3A1/HIN1) 
SCGB3A1, also known as HIN1, is described as a tumor suppressor gene involved 
in cell cycle control, migration and invasion suppression and apoptosis stimulation [58].  
Moreover, higher SCGB3A1 methylation levels were associated with ER positive samples 
and well-differentiated tumors [59, 60], whereas low methylation levels were associated with 
basal-like subtype [45, 48, 59]. 
  
 
 
 
 
AIMS 
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AIMS 
 
BrC is a heterogeneous disease involving genetic and epigenetic modifications. 
Despite the technical advances for early detection, BrC still is the main cause of cancer 
death among women in Europe. More efficient detection tests, able to diagnose and 
characterize BrC may improve the treatment efficacy in BrC patients. 
Epigenetic modifications occur at the onset, development and progression of BrC. 
DNA methylation markers have, thus, emerged as potential diagnostic and prognostic 
biomarkers due to their stability and easy assessment by Polymerase Chain Reaction 
(PCR) technologies. Thus, the major aim of this dissertation is to develop a DNA 
methylation-based test capable of early detecting all the major BrC molecular subtypes. 
Thus, the specific aims of this work were: 
 Assess the methylation status of six genes’ promoters (APC, BRCA1, 
CCND2, FOXA1, RASSF1A and SCGB3A1) in a series of BrC and normal 
breast (NBr) frozen tissues. 
 Define the BrC molecular subtype using IHC and correlate it with the 
methylation levels of the previously indicated six genes’ promoters. 
 Evaluate the association of methylation levels with standard 
clinicopathological parameters and assess the prognostic value of aberrant 
methylation of those six genes’ promoters in a cohort of BrC patients. 
 
 
 
 
 
 
  
 
 
 
 
MATERIAL AND 
METHODS 
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PRELIMINARY DATA 
IHC was performed to identify the molecular subtype of each case BrC included in 
this study. Commercially available antibodies were used for ER (Clone 6F11, mouse, 
Leica), PR (Clone 16, mouse, Leica), ERBB2 (Clone 4B5, rabbit, Roche) and Ki67 (Clone 
MIB-1, mouse, Dako). 
IHC was carried out in BenchMark ULTRA (Ventana, Roche) using ultraView 
Universal DAB Detection Kit (Ventana, Roche) according with manufacturer’s instructions.  
Each case was evaluated by an experienced pathologist. IHC staining was classified 
according to College of American Pathologists recommendations. For ERBB2 
immunostaining, the cases score 2+ were confirmed by fluorescence in situ hybridization. 
Each case was categorized according the guidelines of ESMO (Table 3). The cut-off for 
Ki67 was 15% of positive cells and the cut-off for high vs. low expression of PR was 25%. 
 
PATIENTS AND SAMPLES COLLECTION 
For this study, 137 BrC samples were prospectively collected from patients 
submitted to surgery as 1st treatment from 1996 to 2001, at the Portuguese Oncology 
Institute of Porto. All control samples (NBr) were collected from reduction mammoplasty of 
contralateral breast of BrC patients without breast cancer hereditary syndrome. After 
surgical resection and examination, samples were immediately frozen at -80°C. Relevant 
clinical and pathological data was retrieved from the patient’s clinical charts. 
Five μm frozen sections were cut and stained by hematoxilin-eosin staining and 
histological evaluation was performed by an experienced pathologist. 
DNA EXTRACTION 
DNA extraction was performed by phenol-chloroform method. Ten μm sections from 
fresh-frozen tissues were cut and placed in 15mL tubes. To the fresh-frozen sections 2.700 
mL of SE buffer (75mM NaCl and 25 mM EDTA), 300 μL of 10% SDS and 25 μL of 
proteinase K [20mg/mL(NZYTECH, Portugal)] were added. Samples were incubated at 
55ºC until complete digestion was achieved. Additional proteinase K was added at twice a 
day. 
Subsequent to digestion, all samples were transferred to Phase Lock Light 15mL 
tubes (5 Prime, Germany) previously centrifuged at 4000 rpm for 5 minutes and mixed with 
3mL of phenol-chloroform pH=8 (Sigma-Aldrich, USA).  
After centrifugation, at 4000 rpm for 20 minutes, the aqueous phase was transferred 
to new 15mL tube. For DNA precipitation, 6mL of cold absolute ethanol (Merkmilipore, 
Germany) and 1mL of ammonia acetate at 7.5M (Sigma-Aldrich, USA) were added to 
samples. After mixing, samples were placed at -20°C overnight. 
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Following, samples were centrifuged at 4000 rpm for 20 min and washed in 6mL 
ethanol 70% twice. The air dried pellets and eluted in sterile distilled water (B.Braun, 
Melsungen, Germany). DNA concentration and purity were assessed using NanoDrop Lite 
Spectrophotometer (Nanodrop Technologies, USA) and stored at -20°C until further use. 
METHYLATION ANALYSIS 
Sodium Bisulfite Modification 
Sodium Bisulfite modification is a crucial step for all the methylation studies involving 
PCR and sequencing[61]. This process allows to differentiate methylated from 
unmethylated cytosines. The unmethylated cytosines suffer a sulphonation, deamination 
and desuphonaltion processes and are convert to uracil while methylated cytosine remains 
unaltered. 
Genomic DNA from all samples was modified by sodium bisulfite using EZ DNA 
Methylation-Gold™ Kit (Zymo Research, USA) according to the manufacturer’s guidelines 
(Appendix III).  
To sodium bisulfite modification, it was used 1µg of DNA obtained from fresh frozen 
sections. In the end of protocol modified DNA was eluted with 60μL of sterile distilled water 
and stored at -80°C until further use. 
One μg of CpGenome™ Universal Methylated DNA (Millipore, USA) was also 
modified, according to the method described above and eluted in 20μL of M-elution buffer. 
Quantitative Methylation-Specific PCR (qMSP) 
To analyze methylation levels in our samples was performed quantitative real-time 
methylation specific PCR (qMSP). Methylation specific PCR (MSP) allows the specific 
amplification of methylated or unmethylated alleles[62]. In MSP, the modified DNA is used 
as template and amplify using primers that containing or not CpGs, however MSP is a 
qualitative method [62, 63]. The qMSP is a quantitative method that combines the MSP and 
real-time PCR principles. This method is more sensitive and uses primers with CpGs allows 
the specific amplification of methylated DNA.  
The modified DNA was used as template and samples were submitted to qMSP 
reactions for the target genes: APC, BRCA1, CCND2, FOXA1, RASSF1A and SCGB3A1; 
and for Actin  (ACTβ) gene used as reference gene. 
Reactions were performed in 96-well plates using Applied Biosystems 7500 Real- 
Time System (Thermo Fisher Scientific, USa). Briefly, per each well were added 2 μL of 
modified DNA and 5 μL of 2X KAPA SYBR FAST qPCR Master Mix. The primer volume 
used was 0.3µL from a 10mM solution of forward and reserve primers, except to ACTβ 
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which primer volume used was 0.4µL. Sterile distilled water was added until 10 μL of 
reaction volume were achieved. Primer sequences are listed in Table 4. 
Table 4 – Primers sequences and qMSP conditions for each gene studied. 
Gene Primers  
Annealing 
Temperature ºC 
ACTβ 
F – 5’ TGG TGA TGG AGG AGG TTT AGT AAG T 3’  
60ºC R – 5’ ACC AAT AAA ACC TAC TCC TCC CTT AA 
3’ 
APC 
F – 5’ TGT GTT TTA TTG CGG AGT GC 3’ 
62ºC 
R – 5’ CAC ATA TCG ATC ACG TAC GC 3’ 
BRCA1 
F – 5’ TTT CGT GGT AAC GGA AAA GC 3’ 
60ºC 
R – 5’ ATC TCA ACG AAC TCA CGC CG 3’ 
CCND2 
F – 5’ TTT GAT TTA AGT ATG CGT TAG AGT ACG 
3’ 62ºC 
R – 5’ ACT TTC TCC CTA AAA ACC GAC TAC G 3’ 
FOXA1 
F – 5’ CGA CGT TAA GAC GTT TAA GC 3’ 
62ºC 
R – 5’ CGC TCA ACG TAA ACA TCT TAC 3’ 
RASSF1A 
F – 5’ AGC GAA GTA CGG GTT TAA TC 3’ 
60ºC 
R – 5’ ACA CGC TCC AACC GA ATA 3’ 
SCGB3A1 
F – 5’ GTA CGG TCG TGA GCG GAG C 3’ 
64ºC 
R – 5’ GAA ACT TCT TAT ACC CGA TCC TC 3’ 
 
The PCR program consisted of a period of 3 minutes at 95°C for enzyme activation 
followed by 45 cycles with 3 seconds at 95°C (for DNA denaturation) and 30 seconds at the 
temperature indicated in Table 4 (for annealing, extension and data acquisition). 
All the samples were run in triplicated and in each plate 2 wells contained a negative 
control. The modified CpGenome™ Universal Methylated DNA was used as positive control 
and it was diluted in five serial dilutions by a 5x dilution factor. These serial dilutions were 
run in each plate and were used to generate a standard curve thus allowing absolute 
quantification as well as ascertaining PCR efficiency. All plates had an efficiency between 
90-100%. 
For each gene, relative methylation levels were calculated as the ratio between the 
target gene mean quantity and ACTβ mean quantity: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙𝑠 =
𝑀𝑒𝑎𝑛 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒
𝑀𝑒𝑎𝑛 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝐴𝐶𝑇𝛽
×1000 
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STATISTICAL ANALYSIS 
The frequency, median and interquartile range of promoter methylation levels of 
normal tissue/control samples were determined.  
Non-parametric tests were performed to determine statistical significance in all the 
comparisons made. In particular, Kruskall-Wallis test was used in comparisons between 3 
or more groups, whereas Mann-Whitney U test was used for comparisons between two 
groups.  
Logistic regression models were also built in order to evaluate the potential of using 
the targets as a panel to increase performance.  To assessing the targets’ performance as 
biomarkers, ROC curves were built. Moreover, biomarker parameters [specificity, 
sensitivity, positive predictive value (PPV), negative predictive value (NPV) and accuracy] 
were determined using the formulas provided in Table 5. For this, the cut-off established 
was the highest value obtained by the ROC curve analysis [sensitivity + (1-specificity)]. To 
categorize samples as methylated or unmethylated, a cutoff value was chosen based on 
cutoff obtained by the ROC curve analysis for each gene. 
Spearman nonparametric correlation test was performed to correlate methylation 
levels and age. 
Table 5 – Formulas used for biomarker parameters calculation. 
Tumor vs. Control 
 
Sensitivity (%) (C/A) x100 
 Tumor Control Specificity (%) (F/B) x 100 
Total A B PPV (%) (C/(C+D)) x 100 
> cut-off C D NPV (%) (F/(E+F)) x 100 
< cut-off E F Accuracy (%) [(C+F)/(A+B)] x 100 
 
Disease-specific survival curves and disease-free survival curves (Kaplan–Meier 
with log rank test) were computed for standard clinicopathological variables and for 
categorized methylation status. A Cox-regression model comprising all significant variables 
(multivariable model) was computed to assess the relative contribution of each variable to 
the follow-up status.  
Two-tailed P-values were derived from statistical tests, using a computer assisted 
program (SPSS Version 20.0, Chicago, IL), and results were considered statistically 
significant at P < 0.05, with Bonferroni´s correction for multiple tests, when applicable  
Graphics were assembled using GraphPad 6 Prism (GraphPad Software, USA).
 
 
 
 
 
RESULTS 
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CLINICAL SAMPLES 
For the purpose of this study, clinical tissue samples of NBr and BrC, stored at the 
Department of Pathology were used after institutional ethical committee’s approval (CES 
120/015). The relevant clinical and pathological data are presented in Table 6.  
Table 6 – Clinical and pathological data of al Breast Cancer (BrC) and Normal Breast (NBr) samples used in 
this study. 
Clinicopathologic features BrC NBr 
Patients (n) 137 18 
Age median (range) 62 (33-88) 54 (40-70) 
Molecular subtype (no). 
Luminal A 
Luminal B 
ERBB2 overexpression 
TNBC 
 
29 
74 
12 
22 
n.a. 
Histological Type 
Invasive Ductal Carcinoma 
Invasive Lobular Carcinoma 
Special Subtype Carcinomas  
Mixed Type Carcinoma 
 
116 
8 
5 
8 
n.a. 
Grade (no.) 
G1 
G2 
G3 
Not determined 
  
13 
63 
56 
5 
n.a. 
Estrogen Receptor Status 
Positive 
Negative 
 
35 
102 
n.a. 
Progesterone Receptor Status 
Positive 
Negative 
 
66 
71 
n.a. 
ERBB2 Receptor Status 
Positive 
Negative 
 
25 
112 
n.a. 
Pathological T Stage (no.) 
pT1 
pT2 
pT3 
pT4 
pTx 
 
42 
84 
7 
2 
2 
n.a. 
Pathological N Stage (no.) 
pN0 
pN1 
pN2 
pN3 
pNx 
 
52 
45 
17 
19 
4 
n.a. 
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Stage (no.) 
I 
II 
III & IV 
Not determined 
 
21 
71 
41 
4 
n.a. 
BrC – Breast Cancer; NBr – Normal Breast; n.a. – non applicable; TNBC – Triple Negative Breast Cancer; 
 
ASSESSMENT OF THE METHYLATION LEVELS IN BRC AND 
NBR TISSUE SAMPLES  
To verify whether the methylation levels of selected genes were cancer-specific, it 
was evaluated in BrC and NBr tissue samples. The majority of BrC samples presented 
higher levels of methylation at APC, CCND2, FOXA1, RASSF1A and SCGB3A1 promoters 
when compared to NrB samples (p<0.0001, p<0.0001, p=0.0016, p<0.0001 and p<0.0001, 
respectively) (Table 7), whereas for BRCA1, no differences were depicted, and, thus, 
BRCA1 was not further tested as diagnostic biomarker. 
Table 7 – Frequency of positive cases [n(%)] and distribution of methylation levels of cancer-related genes 
[gene/ACTB x1000 median (IQR1)] 
Genes 
NBr BrC 
p value 
n (%) Median (IQR) n (%) Median (IQR) 
APC 0/18 (0%) 
1.053 
(0.548-2.049) 
70/137 
(51%) 
24.010 
(1.423-232.219) 
<0.0001 
BRCA1 
15/18 
(83.3%) 
0.116  
(0.056-0.297) 
135/137 
(98.5%) 
0.137 
(0.052-0.395) 
0.7627 
CCND2 1/18 (5.6%) 
0.064 
(0-0.325) 
93/137 
(67.9%) 
5.551 
(0.345-31.217) 
<0.0001 
FOXA1 0/18 (0%) 
13.595  
(8.822-21.568) 
65/137 
(47.4%) 
28.325  
(13.595-59.779) 
0.0016 
RASSF1A 1/18 (5.6%) 
12.653 
(4.056-21.265) 
113/137 
(82.5%) 
329.841 
(144.128-559.82) 
<0.0001 
SCGB3A1 0/18 (0%) 
0.625 
(0.264-3.078) 
95/137 
(69.3%) 
217.267 
(3.327-575.690) 
<0.0001 
NBr – Normal Breast; BrC – Breast Cancer; IQR – Interquartile Range 
EVALUATION OF THE BIOMARKER DIAGNOSTIC 
PERFORMANCE 
Because the majority of the tested genes showed higher methylation levels in BrC 
than in NBr samples (Figure 10, left panel), ROC curves (Figure 10, right panel) were 
constructed and empirical cut-off value was determined for each gene (Appendix IV). 
                                               
1 IQR – Interquartile Range 
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Figure 10 – Box-plots (left panels) of methylation levels in Normal Breast (NBr) 
and Breast Cancer (BrC) samples of APC (A), CCND2 (C), FOXA1 (E), 
RASSF1A (G) and SCGB3A1 (I) and respective Receiver Operating 
Characteristic Curve (right panel) (B, D, F, H and J). Abbreviations: AUC – Area 
Under the Curve 
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Notably, except for FOXA1, all the genes displayed an Area Under the Curve (AUC) 
higher than 0.80. The empirical cut-off for each gene allowed for the calculation of 
performance for each gene individually (Table 8). APC, FOXA1 and SCGB3A1 showed 
100% specificity for cancer detection, however the negative predictive values (NPV) were 
not higher than 30%. RASSF1A presented the highest sensitivity (82.48 %) and the highest 
accuracy (83.87%). 
Table 8 – Performance of promoter gene methylation as biomarkers for detection of Breast Cancer in 
tissue samples 
Genes Sensitivity % Specificity % PPV % NPV % Accuracy % 
APC 51.09 100.00 100.00 21.18 56.77 
CCND2 67.88 94.44 98.94 27.87 70.97 
FOXA1 47.45 100.00 100.00 20.00 53.55 
RASSF1A 82.48 94.44 99.12 41.46 83.87 
SCGB3A1 69.34 100.00 100.00 30.00 72.90 
PPV – Positive Predictive Value; NPV – Negative Predictive Value 
 
The combination of multiple genes was tested, as well, in an attempt to improve the 
performance. The best results were achieved by the panel comprising APC, FOXA1 and 
RASSF1A which showed an accuracy of 94.19% and an AUC of 0.9570 (Table 9, Figure 
11). This three-gene panel detected BrC with 94.16% sensitivity, 94.4% specificity and a 
remarkable PPV. 
Table 9 – Performance of promoter gene methylation as biomarkers for detection of Breast Cancer in 
tissue samples 
Genes Sensitivity 
% 
Specificity 
% 
PPV 
% 
NPV 
% 
Accuracy % 
APC/FOXA1/RASSF1A 94.16 94.44 99.23 68.00 94.19 
PPV – Positive Predictive Value; NPV – Negative Predictive Value 
 
 
Figure 11 – Receiver Operating Characteristic 
Curve of the 3-gene panel (APC, FOXA1 and 
RASSF1A) in Breast Cancer. 
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EXPLORING EPIGENETIC BIOMARKERS AS MOLECULAR 
SUBTYPE DISCRIMINATORS 
Aiming to discriminate the four major molecular subtypes of BrC, the distribution of 
methylation levels for the six genes according to molecular subtype was carried out (Figure 
12).  
 
Figure 12 – Boxplots of APC (A), BRCA1 (B), CCND2 (C), FOXA1 (D), RASSF1A (E) and SCGB3A1 
(F) methylation levels in the Breast Cancer molecular subtypes. 
However, no significant differences in the promoter methylation levels of the target 
genes were apparent among the molecular subtypes. 
 
ASSOCIATION BETWEEN PROMOTER METHYLATION 
LEVELS AND STANDARD CLINICOPATHOLOGICAL 
PARAMETERS 
APC, BRCA1, CCND2, FOXA1, RASSF1A and SCGB3A1 promoter methylation 
levels did not associate with tumor grade, pathological stage or ERBB2 status. 
Nevertheless, a significant correlation was found between CCND2 and RASSF1A 
methylation levels and BrC patients’ age (R=0.194, p=0.023 and R=0.223, p=0.009, 
respectively). This correlation was not apparent in controls. Additionally, a significant 
association was found between histological subtypes and APC and SCGB3A1 methylation 
levels (Figure 13). The group of Special Subtype Carcinomas (SSC) showed the lowest 
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SCGB3A1 methylation levels in comparison to all the other histological types (Figure 13B) 
(p= 0.0126, p= 0.0446 and p= 0.0225, respectively for IDC, ILC and MTC). Moreover, SSC 
showed lower APC methylation levels than all the others histological types (Figure 13A), 
but significant differences were only attained for Invasive Lobular Carcinomas (ILC), 
(p=0.0293) (Figure 13B). 
 
Figure 13 – Boxplots of APC (A) and SCGB3A1 (B) methylation levels across the 
different Breast Cancer histological types. Abbreviations: IDC – Invasive Ductal 
Carcinoma; ILC – Invasive Lobular Carcinoma; MTC – Mixed Type Carcinoma; 
SSC – Special Subtype Carcinoma 
FOXA1 and RASSF1A methylation levels associated with Hormone Receptor Status 
(Figure 14). BrC positive for both hormone receptors (ER and PR) displayed significantly 
lower FOXA1 methylation levels than ER and PR negative BrC samples (p= 0.0084). The 
same was observed for BrC samples that were only ER positive (p= 0.0319) (Figure 14 A). 
Contrarily, BrC samples positive for both Hormone Receptors showed higher RASSF1A 
methylation levels than ER positive only BrC samples (p= 0.0017). However, no statistical 
differences were observed between hormone receptor positive samples and hormone 
receptor negative samples (Figure 14 B). For the remaining genes no associations were 
disclosed regarding hormone receptor status. 
 
 
Figure 14 – Boxplots of the methylation levels of FOXA1 (A) and RASSF1A (B) 
regarding Hormone Receptor Status. Abbreviations: ER+ – Estrogen Receptor 
Positive; ER- – Estrogen Receptor Negative; PR+ – Progesterone Receptor 
Positive; PR- – Progesterone Receptor Negative   
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SURVIVAL ANALYSIS 
Survival analysis was performed aiming to evaluate the potential prognostic value 
of the six genes’ promoters (APC, BRCA1, CCND2, FOXA1, RASSF1A and SCGB3A1) 
methylation levels. The survival analysis was carried out at 10 years of follow-up. At the 
time of the last follow-up 92 patients (67.2%) were alive with no evidence of cancer, 8 
patients (5.8%) were alive with cancer and 37 patients (27.0%) had deceased, 24 of which 
due to BrC (17.5% of all cases). 
Due to the reduce number of events and/or cases in same categories, some 
clinicopathological features were grouped. Grade was grouped in two categories (G1&G2 
vs. G3), pT stage was grouped in three categories (pT1, pT2 and pT3&pT4), pN Stage was 
grouped in two categories (N0&N1 vs. N2&N3) and stage was grouped in three categories 
(I, II and III&IV). 
Although, methylation levels of any of the studied genes did not associate with 
disease-free survival, statistically significance was found for tumor grade (p=0.041), pN 
stage (p<0.001) and Stage (p=0.038). 
Concerning disease-specific survival the only gene that presented prognostic value 
was FOXA1 categorized by percentile 75 of promoter methylation levels (Figure 15 A). 
Thus, BrC patients with FOXA1 high methylation levels showed shorter disease-specific 
survival compared to BrC patients with low methylation levels. 
 
Figure 15 – Disease-specific survival curves (Kaplan–Meier with log rank test) of FOXA1 methylation (A) and 
clinicopathological parameters [pN Stage (B) and Grade (C)]. Abbreviations – P75 – percentile 75 of methylation 
of FOXA1. 
Moreover, pN2 or pN3 patients disclosed worse disease-specific survival than pN0 
or pN1 patients (Figure 15 B). Similarly, patients with high grade BrC (G3) displayed a worse 
disease-specific survival than patients with low or moderate grade BrC (G1 or G2) (Figure 
15 C). 
A Cox regression analysis was also computed to assess the potential of both 
clinicopathological and epigenetic variables in predicting disease-specific survival (Table 
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10). In this multivariable model, only FOXA1 methylation levels and pN Stage retained 
statistical significance for predicting disease-specific survival. 
Table 10 – Cox regression models assessing the potential of clinical and epigenetic variables in the 
prediction of disease-specific survival for 127 patients with Breast Cancer. 
Disease-
Specific 
Survival 
Variable HR CI (95%) p value 
Univariable Grade 
G1 
G2 & G3 
 
1 
2.725 
 
 
1.155 – 6.428 
 
 
0.022 
pN Stage 
N0 & N1 
N2 &N3 
 
1 
4.061 
 
 
1.814 – 9.089 
 
 
0.001 
FOXA1 
≤P75 
>P75 
 
1 
2.678 
 
 
1.200 – 5.978 
 
 
0.016 
Multivariable  Grade 
G1 
G2 & G3 
 
1 
2.005 
 
 
0.082 – 4.866  
 
 
0.124 
pN Stage 
N0 & N1 
N2 &N3 
 
1 
4.855 
 
 
1.981 – 10.611 
 
 
<0.001 
FOXA1 
≤P75 
>P75 
 
1 
2.710 
 
 
1.161 – 6.324 
 
 
0.021 
HR – Hazard Ratio; CI – Confidence Interval; P75 – Percentile 75 of methylation levels of FOXA1 
To disclose the potential of FOXA1 methylation levels as predictors of disease-
specific survival for each pN Stage category, a stratified disease-specific survival analysis 
was performed (Table 11). Thus, in pN0&pN1 group, patients with high FOXA1 promoter 
methylation levels had a 3.755- fold increased risk of dying from BrC. 
Table 11 – Cox regression model assessing the potential FOXA1 methylation levels in a stratified analysis 
by pN Stage categories in the prediction of disease-specific survival for 132 patients with Breast Cancer. 
Disease-Specific Survival 
Layering 
Variable 
Variable HR CI (95%) p value 
pN0 & pN1 
FOXA1 
≤P75 
>P75 
 
1 
3.755 
 
 
1.091 – 11.722 
 
 
0.035 
pN2 & pN3 
FOXA1 
≤P75 
>P75 
 
1 
2.668 
 
 
0.868 – 8.201 
 
 
0.087 
HR – Hazard Ratio; CI – Confidence Interval; P75 – Percentile 75 of methylation levels of FOXA1 
 
  
 
 
 
 
DISCUSSION 
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DISCUSSION 
At global level, BrC remains the major cause of cancer-related death in women. 
Mammographic-based screening led to an increase in the incidence of BrC diagnosis and 
a concomitant reduction in mortality between 28 and 45 % in countries in which it was 
implemented [10, 13, 64, 65]. Mammography is able to detect BrC with 70% sensitivity and 
92% specificity [66]. However, the mammography-based screening is dependent of 
radiologist experience and the accuracy of diagnosis is influenced by breast density [66]. 
Moreover, the benefit of mammographic BrC screening in women between 40-49 years is 
still a matter of controversy [64] and overdiagnosis (i.e., “detection of cancers that would 
never have been found if it was not for the screening test” and includes all cancers, in situ 
or invasive [65]) due to mammography screening is becoming an important issue in the 
scientific community. Efforts to find new diagnosis biomarkers with sensitivity and specificity 
superior to those of mammography and that might allow for stratification of BrC 
aggressiveness is an ongoing field of research. Thus, the purpose of this study was to 
assess the potential of DNA methylation as diagnostic and prognostic marker for BrC. 
Currently, DNA methylation is acknowledged as an early event in cancer 
development, including BrC [55, 67, 68]. Several tumor suppressor genes have been found 
hypermethylated in precursor lesions of invasive carcinoma indicating that DNA methylation 
is an early event in breast carcinogenesis [55, 68-70]. Indeed, aberrant DNA methylation 
has gained recognition as a cancer-associated event, and the definition of tumor-specific 
methylome has become the focus of multiple studies [67]. Indeed, DNA methylation has 
been proposed as a valuable cancer biomarker owing to its link to tissue-specific gene 
silencing [71, 72]. 
In this dissertation, we showed that five out of the six candidate genes might be 
suitable markers for BrC diagnosis/detection (APC, CCND2, FOXA1, RASSF1A and 
SCGB3A1). These genes were able to accurately discriminate NrB from invasive BrC 
tissues, confirming in tissue samples the diagnostic potential of APC, CCND2, RASSF1A 
and SCGB3A1 methylation as diagnosis marker that we previously reported for fine-needle 
aspirate washings of breast lesions [45, 50]. Remarkably, FOXA1 promoter also 
demonstrated significant differences in methylation levels between BrC and NrB samples. 
Although there are multiple studies associating FOXA1 expression and BrC prognosis and 
subtyping, this is the first study, to the best of our knowledge, that unveiled the potential of 
FOXA1 methylation as diagnostic BrC marker. Conversely, in accordance with a previous 
publication, BRCA1 methylation did not discriminate BrC from NBr tissue in our sample set 
[73]. This finding is also in line with a previous study from our research team that found no 
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significant difference in BRCA1 methylation levels among BrC, NrB and fibroadenoma 
samples obtained through FNB [45].  
Moreover, we sought to define a small panel of methylated genes that might 
accurately detect BrC, maximizing sensitivity and specificity. However, a low NPV was 
obtained, probably due to the small number of NBr samples. To overcome this limitation, 
we combined a highly sensitive methylation marker (RASSF1A) with highly specific 
methylation markers (APC and FOXA1) thus accomplishing a panel which demonstrated 
sensitivity, specificity and accuracy over 94%, as well as high PPV. SCGB3A1 and CCND2 
methylation were not considered for this panel because they were not able to detect TNBC 
(data not shown). ROC curve analysis confirmed the good performance of the selected 
panel, with an AUC above 0.95. Although FOXA1 methylation has not been previously 
reported as a diagnostic marker, RASSF1A and APC methylation were already reported as 
part of methylation panel developed for FNB samples [45, 50]. The initial study reported a 
four-gene panel for detection of BrC in FNB (APC, CCND2, RASSF1A and SCGB3A1) 
although due to the scarcity of DNA the panel was reduced to three-genes: APC, CCND2 
and RASSF1A) [45, 50]. The different panels proposed might be explained by differences 
among populations or the type of biological samples (tissue and body fluids) [49, 57, 74, 
75]. Thus, large multicenter prospective studies are critical to validate the clinical use of the 
three-gene panel proposed herein.  
Our second aim was to associate the six genes’ promoter methylation levels with 
BrC molecular subtypes defined by IHC, following the updated ESMO guidelines for 
molecular classification (Table 3). Nevertheless, no associations were found between 
promoter methylation levels and BrC molecular subtypes. IHC has some limitations for the 
classification of TNBC/basal tumors and discrimination between luminal subtypes A and B 
[21, 30, 31]. Moreover, our cohort is composed of consecutive samples from BrC patients 
diagnosed between 1996 and 2001 whose molecular subtype frequencies were similar to 
those expected. Thus, the number of ERBB2 and TNBC tumor subtypes is rather limited, 
although it parallels the lower frequencies commonly found in a consecutive cohort of BrC 
patients. In fact, studies reporting associations between DNA methylation and specific 
molecular subtypes have used a similar frequency of all the subtypes or have only analyzed 
a specific subtype [43, 47, 48]. 
Furthermore, although IHC subtyping is more feasible and less expensive, those 
studies have used several microarrays platforms. Additionally, analysis of aberrant DNA 
methylation was also performed using different methods. Indeed, using array-based and 
whole genome-analysis for DNA methylation, a correlation between DNA methylation 
pattern and molecular subtypes was found, revealing BrC subsets with different prognosis 
within each BrC molecular subtype [44, 76-79]. Therefore, differences in molecular 
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subtypes’ classification and IHC cut-off definitions as well as in aberrant methylation 
analyses prevents definitive comparisons among studies. 
Concerning our last aim, i.e., the prognostic significance of gene-specific aberrant 
promoter methylation in BrC, the association between genes’ promoter methylation and 
standard clinicopathological parameters (histological subtype, grade, hormone receptor 
status, ERBB2 status, pathological T and N stage and stage) was assessed for all candidate 
genes. Higher APC and SCGB3A1 promoter methylation levels significantly associated with 
histological subtype. Generally, SSC showed lower APC methylation levels, but a significant 
difference was only depicted between SSC and ILC. Moreover, SSC displayed lower 
SCGB3A1 methylation levels than any other histological subtype. Due to SSC heterogeneity 
and low frequency most of the studies do not associate methylation levels with SSC. 
However, Tisserand and colleagues reported the lack of SCGB3A1 methylation in medullary 
carcinoma of the breast, a SSC type also included in TNBC [80]. 
Furthermore, in our study, hormone receptor status, an important prognostic marker, 
associated with RASSF1A and FOXA1 methylation levels. Indeed, ER+/PR+ BrC tumors 
displayed higher RASSF1A methylation levels than ER+ BrC. Although, RASSF1A 
methylation has been shown to be an ER status discriminator [43, 56], we did not find 
differences considering only ER status – luminal vs. non-luminal BrC samples (data not 
shown), in accordance with previous reports [60, 81]. Moreover, most of the studies 
categorize hormone receptor status only into two categories: positive (positive for ER and/or 
PR) and negative. However, it is currently accepted that ER positive/PR positive and ER 
positive/PR negative BrC have different prognosis [9, 16]. Contrarily to RASSF1A, FOXA1 
methylation levels were significantly lower in ER+/PR+ BrC. Although, FOXA1 methylation 
is still poorly studied in BrC, FOXA1 hypermethylation was described in basal BrC cell lines, 
a negative hormone receptor subtype [52, 53].  
Due to high mortality BrC rate one of our aims was also to assess the prognostic 
value of the selected aberrantly methylated genes in BrC. Thus, concerning disease-free 
survival only standard clinicopathological parameters were associated with survival in 
univariable analysis. Nevertheless, regarding disease-specific survival, FOXA1 
methylation, grade and pN stage were associated with patient outcome.  
Although, ER and PR expression were previously associated with favorable 
prognosis and predicted response to endocrine therapy [9, 16], in our cohort hormone 
receptor status did not predict outcome. Because no selection bias was apparent in our 
series, this lack of prognostic value might be associated with the determination of hormone 
receptor status at diagnosis (some case were determined by pharmacology) leading to 
discrepancies to the results obtained by IHC and may have led to different therapeutic 
strategies. Remarkably, high FOXA1 methylation levels (above percentile 75) associated 
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with shorter disease-specific survival. The cut-off value was based in previous studies 
performed in FNB from BrC patients that associated high RASSF1A methylation levels with 
shorter disease-free survival [50]. Empirically, the association of promoter methylation 
levels and gene expression correlates with the density of CpG dinucleotide methylation. 
Therefore, higher promoter methylation levels are more likely to cause a decrease in mRNA 
expression and, thus, a more effective gene silencing. Although FOXA1 methylation levels 
have not been previously reported as prognostic parameters in BrC, FOXA1 expression 
was previously associated with good prognosis and response to endocrine therapy [82, 83]. 
Therefore, FOXA1 promoter methylation might be the mechanism underlying FOXA1 
downregulation that was associated with BrC carrying worse prognosis. 
Multivariable analysis showed that the prognostic value of FOXA1 methylation was 
dependent of pN stage. Indeed, FOXA1 methylation prognostic value was limited to pN0 & 
pN1 group, which might be explained by the small number of cases in this group (n=36). 
Further studies are needed to better understand the potential of FOXA1 methylation in BrC 
prognostication. 
Moreover, in this series of BrC patients, we were not able to verify the prognostic 
value of RASSF1A methylation levels. Albeit RASSF1A hypermethylation was reported to 
be a poor prognostic marker in BrC, associated with shorter disease-free survival and 
shorter disease-specific survival [50, 84, 85], other studies had results similar to ours [86-
88]. These differences might be due to variations among patient populations and 
methodologies used for assessment of methylation levels. However, a meta-analysis of 
published data suggests that RASSF1A methylation is, indeed, associated with poor 
prognosis both for disease-free and specific-disease survival [89]. Thus, larger prospective 
studies are still needed to further establish the clinical utility of RASSF1A methylation in 
BrC. 
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CONCLUSIONS AND FUTURE PERSPECTIVES  
In this study we confirmed the value of DNA methylation as BrC diagnostic marker, 
as previously reported by us in FNB of BrC patients. Indeed, a three-gene panel (APC, 
FOXA1 and RASSF1A) demonstrated high specificity, sensitivity and accuracy for BrC 
diagnosis. As future perspective, we expect to validate this panel as diagnostic marker in 
plasma samples. The potential of liquid biopsies, including blood samples, for cancer 
diagnosis / early detection has been the focus of many recent studies owing to its less 
invasive nature. These samples are enriched in circulating cell-free DNA (cfDNA) which is 
not associated with any cell fraction [90]. Several studies reported an increase of cfDNA in 
cancer patients and this has been validated as tumor biomarker in those patients [91, 92]. 
Moreover, detection of DNA-methylation in serum and plasma was already reported for 
diagnostic, monitoring and prognostic purposes in BrC patients, although with suboptimal 
performance [49, 57, 93, 94]. Thus, we will explore the possibility of using a DNA-
methylation based test as a diagnosis marker with improved sensitivity and specificity. 
Contrarily to our initial expectation, no correlation was found between DNA 
methylation and BrC molecular subtype. Because this might be due to the sample size, we 
intend to enrich the patient cohort with ERBB2 overexpressing and TNBC subtypes.  
Moreover, we revealed the potential of FOXA1 methylation as prognostic marker. 
High FOXA1 methylation levels associated with shorter disease-specific survival dependent 
on pN stage. Thus, we intend to increase the number of pN2&pN3 tumors to verify whether 
FOXA1 methylation levels might have prognostic value at more advanced stages. 
Additionally, to verify whether methylation is the main silencing mechanism of FOXA1, we 
will determine whether FOXA1 methylation levels correlate inversely with mRNA expression 
levels. 
Further studies, preferably involving multiple institutions, are required to further 
validate these findings. FOXA1 promoter methylation might constitute an important 
prognostic ancillary tool for assisting clinical decision making.  
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Appendix I – Anatomic Stage/Prognostic Groups adapted 
from [15] 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 
T1 
N1mi 
N1mi 
M0 
M0 
Stage IIA T0 
T1  
T2 
N1  
N1  
N0 
M0 
M0 
M0 
Stage IIB T2 
T3 
N1 
N0 
M0 
M0 
Stage IIIA T0, T1, T2 
T3 
T4 
N2 
N1, N2 
N0, N1, N2 
M0 
M0 
M0 
Stage IIIB T4 N0, N1, N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
 
 
 
 
 
 
 
 
  
III 
 
Appendix II –TNM classification of carcinomas of the breast 
adapted from [15] 
Primary tumor (T)* 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis 
(DCIS) 
Ductal carcinoma in situ 
Tis 
(LCIS) 
Lobular carcinoma in situ 
Tis 
(Paget’s) 
Paget’s disease of the nipple NOT associated with invasive carcinoma and/or 
carcinoma in situ (DCIS and/or LCIS) in the underlying breast parenchyma. 
Carcinomas in the breast parenchyma associated with Paget’s disease are 
categorized based on the size and characteristics of the parenchymal disease, 
although the presence of Paget’s disease should still be noted  
T1 Tumor ≤20 mm in greatest dimension 
T1mi Tumor ≤1 mm in greatest dimension 
T1a Tumor >1 mm but ≤5 mm in greatest dimension 
T1b Tumor >5 mm but ≤10 mm in greatest dimension  
T1c Tumor >10 mm but ≤20 mm in greatest dimension 
T2 Tumor >20 mm but ≤50 mm in greatest dimension 
T3 Tumor >50 mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall and/or to the skin 
(ulceration or skin nodules). 
Note: Invasion of the dermis alone does not qualify as T4 
T4a Extension to the chest wall, not including only pectoralis muscle 
adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema (including peau 
d’orange) of the skin, which do not meet the criteria for inflammatory carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma  
Regional Lymph Nodes (N) – Clinical 
Nx  Regional lymph nodes cannot be assessed (e.g previously removed) 
N0 No regional lymph node metástases 
N1 Metastases to movable ipsilateral level I, II axillary lymph node(s) 
IV 
 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or 
matted; or in clinically detected ** ipsilateral internal mammary nodes in the 
absence of clinically evident axillary lymph node metastases 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another 
(matted) or to other structures 
N2b Metastases only in clinically detected** ipsilateral internal mammary nodes and 
in the absence of clinically evident level I, II axillary lymph node metastases 
N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or 
without level I, II axillary lymph node involvement; or in clinically detected** 
ipsilateral internal mammary lymph node(s) with clinically evident level I, II 
axillary lymph node metastases; or metastases in ipsilateral supraclavicular 
lymph node(s) with or without axillary or internal mammary lymph node 
involvement 
N3a Metastases in ipsilateral infraclavicular lymph node(s) 
N3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph 
node(s) 
N3c Metastases in ipsilateral supraclavicular lymph node(s) 
Regional Lymph Nodes (N) – Pathological 
pNX Regional lymph nodes cannot be assessed (e.g., previously removed, or not 
removed for pathologic study) 
pN0 No regional lymph node metastasis identified histologically 
pN1 Micrometastases; or metastases in 1–3 axillary lymph nodes; and/or in internal 
mammary nodes with metastases detected by sentinel lymph node biopsy but 
not clinically detected ** 
pN1mi Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none 
greater than 2.0 mm) 
pN1a Metastases in 1–3 axillary lymph nodes, at least one metastasis greater than 2.0 
mm 
pN1b Metastases in internal mammary nodes with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
detected ** 
pN1c Metastases in 1–3 axillary lymph nodes and in internal mammary lymph nodes 
with micrometastases or macrometastases detected by sentinel lymph node 
biopsy but not clinically detected*** 
pN2 Metastases in 4–9 axillary lymph nodes; or in clinically detected ** internal 
mammary lymph nodes in the absence of axillary lymph node metastases 
V 
 
pN2a Metastases in 4–9 axillary lymph nodes (at least one tumor deposit greater than 
2.0 mm) 
pN2b Metastases in clinically detected** internal mammary lymph nodes in the 
absence of axillary lymph node metastases  
pN3 Metastases in ten or more axillary lymph nodes; or in infraclavicular (level III 
axillary) lymph nodes; or in clinically detected** ipsilateral internal mammary 
lymph nodes in the presence of one or more positive level I, II axillary lymph 
nodes; or in more than three axillary lymph nodes and in internal mammary 
lymph nodes with micrometastases or macrometastases detected by sentinel 
lymph node biopsy but not clinically detected** ; 
or in ipsilateral supraclavicular lymph nodes 
pN3a Metastases in ten or more axillary lymph nodes (at least one tumor deposit 
greater than 
2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes 
pN3b Metastases in clinically detected *** ipsilateral internal mammary lymph nodes 
in the presence of one or more positive axillary lymph nodes; or in more than 
three axillary lymph nodes and in internal mammary lymph nodes with 
micrometastases or macrometastases detected by sentinel lymph node biopsy 
but not clinically detected *** 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
Metastasis (M)*** 
M0 No clinical or radiographic evidence of distant metastases 
M1 Distant detectable metastases as determined by classic clinical and radiographic 
means and/or histologically proven larger than 0.2 mm 
*T classification is the same regardless of whether it is based on clinical or pathological criteria; ** “Clinically 
detected” is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination 
and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based 
on fine needle aspiration biopsy with cytologic examination; ***M classification is the same regardless of whether 
it is based on clinical or pathological criteria. 
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Appendix III – Sodium bisulfite modification using EZ DNA 
Methylation-Gold™ Kit 
Genomic DNA from all samples was modified by sodium bisulfite using EZ DNA 
Methylation-Gold™ Kit (Zymo Research, USA) according to the manufacturer’s guidelines. 
To sodium bisulfite modification, it was used 1µg of DNA obtained from fresh frozen 
sections. From each sample, DNA amount required was added to sterile distilled water up 
to a final volume of 20μL according to each sample concentration. In a PCR tube, 130μL of 
the CT Conversion Reagent was added to the samples DNA and incubated in The Applied 
Biosystems Veriti 96-Well Thermal Cycler (Thermo Fisher Scientific, USA) at 98ºC for 10 
minutes, 64ºC for 3 hours. 
Following the incubation, samples were transferred to a Zymo-Spin™ IC Column 
with 600μL of M-Binding Buffer. The columns were centrifuged at 10 000 rpm for 30 
seconds, washed with 100 µL of M-Wash Buffer and centrifuged again. To each column 
was added 200µL of M-Desulphonation Buffer and let stand for 20 minutes at room 
temperature, followed by a centrifugation 10,000 rpm for 30 seconds to buffer discarded. 
The columns were washed twice with 200μL of M-Wash Buffer followed by a centrifugation 
at 10,000 rpm for 30 seconds. 
At last, the columns were placed in 1.5mL microcentrifuge tube and DNA was eluted 
with 60μL of sterile distilled water for 5 minutes followed by a centrifugation at 13,000 rpm 
for 30 seconds. The modified DNA was stored at -80°C until further use. 
One μg of CpGenome™ Universal Methylated DNA (Millipore, USA) was also 
modified, according to the method described above and eluted in 20μL of M-elution buffer. 
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Appendix IV – Empirical Cut-off for each gene based in ROC 
Curve analysis  
Gene Cut-off 
APC 16.9889 
CCND2 1.13523 
FOXA1 30.6928 
RASSF1A 62.2572 
SCGB3A1 23.0525 
 
 
